Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
INSIDE INFORMATIONREGULATED INFORMATION ...
Nyxoah ( NYXH ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
INSIDE INFORMATIONREGULATED INFORMATION ...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio - Nyxoah ( NASDAQ:NYXH )
Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah's Chairman and Management, and a convertible bond.
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
3 Rule Breaker Investing Hacks From David Gardner's Latest Book
Check out a few highlights from the latest book by David Gardner, co-founder of The Motley Fool.
Nvidia To Rally Around 73%? Here Are 10 Top Analyst Forecasts For Monday - Core Scientific ( NASDAQ:CORZ ) , Boeing ( NYSE:BA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group raised Ecolab Inc. ( NYSE:ECL ) price target from $265 to $300.
These Analysts Revise Their Forecasts On ResMed Following Q1 Results - ResMed ( NYSE:RMD )
ResMed Inc. ( NYSE:RMD ) reported better-than-expected earnings for the first quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.50 per share.
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
ResMed ( RMD ) Q1 Earnings and Revenues Beat Estimates
ResMed (RMD) delivered earnings and revenue surprises of +2.41% and +0.94%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to ResMed ( RMD ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Do Options Traders Know Something About ResMed Stock We Don't?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
ResMed ( RMD ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring
GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.
HIMS Stock Declines Despite Launch of New Specialty in Women's Health
Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.
SLB To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Tuesday - IDEAYA Biosciences ( NASDAQ:IDYA ) , Eversource Energy ( NYSE:ES )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays cut Paylocity Holding Corporation ( NASDAQ:PCTY ) price target from $195 to $175.
Here's Why ResMed ( RMD ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
Abbott ( ABT ) Q3 Earnings Meet Estimates
Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BD Stock Down Despite Making Progress in the Treatment of PAD Lesions
BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.
BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow
BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.
5 Low-Leverage Stocks to Buy as Market Takes a Tumble
As markets tumble, low-leverage stocks like RMD, SAFRY, PNR, CASY, and DRS offer safer investment options for steady returns.
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
SAN DIEGO, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes.
Neogen ( NEOG ) Q1 Earnings Lag Estimates
Neogen (NEOG) delivered earnings and revenue surprises of -20.00% and +2.96%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Why ResMed ( RMD ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nyxoah Expands in the Middle East to Provide Wider Access to Genio
NYXH expands in the Middle East after Abu Dhabi's first Genio implant, aiming to broaden access for OSA patients.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.
Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.
This Target Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - AeroVironment ( NASDAQ:AVAV ) , Abercrombie & Fitch ( NYSE:ANF )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
SAN DIEGO, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, ...
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 - ResMed ( NYSE:RMD )
SAN DIEGO, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- Resmed RMDRMD ) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at ...
Here's Why ResMed ( RMD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care ...
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority - ResMed ( NYSE:RMD )
SAN DIEGO, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Resmed RMDRMD ) , the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights initiative dedicated to advancing the science and ...
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Here's Why ResMed ( RMD ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among ...
AI in Remote Patient Monitoring ( RPM ) Market to Reach USD 8,438.5 Million by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- The global AI in remote patient monitoring market, valued at US$1551.8 million in 2023, stood at US$1,967.7 million in 2024 and is projected to advance at a resilient CAGR of 27.5% from 2024 to 2030, culminating in a forecasted valuation of ...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, ...
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - ResMed ( NYSE:RMD )
Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation
Nyxoah Secures FDA Clearance for Genio System to Treat Sleep Apnea
NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.
Why ResMed ( RMD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why ResMed ( RMD ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
ResMed RMD Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 31, 2025 at 8:30 p.m. ETChief Executive Officer - Mick FarrellContinue reading ...
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings - ResMed ( NYSE:RMD )
Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus ...
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Apple ( NASDAQ:AAPL ) , Amazon.com ( NASDAQ:AMZN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Raymond James raised KLA Corporation KLAC price target from $850 to $950.
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
